Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.
Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.
Our news collection prioritizes accuracy and timeliness, offering:
• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news
Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.
Enveric Biosciences (NASDAQ: ENVB) announced the presentation of its lead programs' results at the 6th International Neurology & Brain Disorders Conference in Orlando, Florida, from October 24-26, 2022. The poster presentations will showcase innovative drug candidates for anxiety, depression, and addiction disorders, highlighting EVM201's novel psilocin prodrugs and EVM301's methods for future drug candidate discovery. Dr. Peter Facchini expressed optimism about advancing their drug discovery program aimed at enhancing mental health treatments.
Enveric Biosciences (NASDAQ: ENVB) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12-14, 2022. President & COO Avani Kanubaddi will present on September 14 at 2:00 p.m. ET. Attendees can register here. Enveric focuses on developing innovative psychedelic-inspired medicines for mental health.
Enveric Biosciences (NASDAQ: ENVB) has appointed three experienced leaders to its Board of Directors: Michael D. Webb, Bevin O’Neil, and Frank Pasqualone. These new board members bring decades of expertise in healthcare, business operations, and global market dynamics. Dr. Joseph Tucker, CEO, expressed enthusiasm for their contributions at this pivotal time for the company, which is focused on developing psychedelic-inspired mental health medicines.
Enveric Biosciences, Inc. (NASDAQ: ENVB) has completed a registered direct offering of 375,000 shares of common stock, raising approximately $8 million before expenses. Additionally, a private placement was conducted for 625,000 shares under similar terms. The offerings included preferred investment options that allow the purchase of an equal number of shares at an exercise price of $7.78. Proceeds will support working capital and corporate purposes. The company has also amended existing warrants to reduce their exercise price to $7.78 from $27.50.
Enveric Biosciences (NASDAQ: ENVB) has entered into definitive agreements for the purchase of 1,000,000 shares of its common stock through a registered direct offering and private placement, priced at $8.00 per share. The total expected gross proceeds from these offerings are approximately $8 million, intended for working capital and corporate purposes. Additionally, existing warrants will be amended to reduce their exercise price to $7.78 per share. The closing is anticipated around July 26, 2022, subject to customary conditions.
Enveric Biosciences (NASDAQ: ENVB) announced a 1-for-50 reverse stock split effective July 14, 2022. This adjustment will reduce the outstanding shares from approximately 52.7 million to 1.05 million. Shareholders will not need to exchange certificates, as adjustments will be made automatically for shares held in brokerage accounts. This split is aimed at improving the company's stock price and maintaining its listing on the Nasdaq Capital Market. The company focuses on developing psychedelic-inspired mental health medicines.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, announced participation in three key conferences: the A.G.P. Summer Healthcare Conference on June 21-22, the Gravitas Los Angeles Summit on June 22, and the H.C. Wainwright Mental Health Conference on June 27. CEO Dr. Joseph Tucker will represent the company at these events, highlighting its commitment to developing innovative solutions for mental health issues affecting patients globally.
Enveric Biosciences (NASDAQ: ENVB) announced that President Avani Kanubaddi will participate in the virtual Microdose Psychedelic Capital Conference on May 26, 2022, at 4:05 p.m. ET. During the panel titled 'The Spinoffs - Divide and Conquer', topics will include recent spinoffs among publicly traded companies. Interested attendees can register here. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications at EnvericBio@kcsa.com.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, will have CEO Dr. Joseph Tucker participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. His presentation will be available on-demand starting May 24 at 7:00 a.m. ET. This event highlights Enveric's dedication to advancing mental health solutions, aiming to assist patients with conditions like PTSD and cancer-related distress. For further details or to arrange a meeting with management, interested parties should contact H.C. Wainwright.
Enveric Biosciences (NASDAQ: ENVB) announced plans to spin off its cannabinoid pipeline into a subsidiary, Acanna Therapeutics Inc., through a dividend to shareholders. This strategic move aims to create two separate biotechnology companies focusing on psychedelic-inspired mental health treatments and cannabinoid therapies. The spin-off is contingent on Acanna meeting Nasdaq listing qualifications and has secured $1 million in initial funding, with potential additional funding of $4 million upon completion. The goal is to enhance resource allocation and value creation for both companies.
